In this Phase @b double-blind , placebo-controlled study , treatment-naive adults with HCV genotype @ ( N = @ ) or @ ( N = @ ) infection were randomly assigned ( @:@:@ ) to daclatasvir @mg or @mg , or placebo once daily plus weekly peginterferon-alfa-@a and twice-daily ribavirin .